Teachers Advisors LLC Increases Position in Omeros Co. (OMER)

Teachers Advisors LLC boosted its stake in Omeros Co. (NASDAQ:OMER) by 35.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 116,400 shares of the biopharmaceutical company’s stock after acquiring an additional 30,544 shares during the period. Teachers Advisors LLC owned about 0.24% of Omeros worth $2,841,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in OMER. Advisors Asset Management Inc. acquired a new position in Omeros in the third quarter valued at $301,000. MetLife Investment Advisors LLC increased its stake in Omeros by 54.8% in the third quarter. MetLife Investment Advisors LLC now owns 33,221 shares of the biopharmaceutical company’s stock valued at $811,000 after purchasing an additional 11,761 shares during the period. Man Group plc acquired a new position in Omeros in the third quarter valued at $286,000. Tocqueville Asset Management L.P. increased its stake in Omeros by 24.7% in the third quarter. Tocqueville Asset Management L.P. now owns 23,700 shares of the biopharmaceutical company’s stock valued at $579,000 after purchasing an additional 4,700 shares during the period. Finally, Foresite Capital Management IV LLC acquired a new position in Omeros in the third quarter valued at $8,690,000. 47.19% of the stock is owned by hedge funds and other institutional investors.

Shares of Omeros stock opened at $13.45 on Wednesday. Omeros Co. has a 52-week low of $8.36 and a 52-week high of $27.00. The stock has a market cap of $664.07 million, a PE ratio of -17.03 and a beta of 3.59.

A number of research analysts have commented on OMER shares. BidaskClub upgraded shares of Omeros from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, October 17th. ValuEngine upgraded shares of Omeros from a “hold” rating to a “buy” rating in a research note on Friday, October 19th. HC Wainwright set a $34.00 price objective on shares of Omeros and gave the company a “buy” rating in a research note on Wednesday, October 24th. Maxim Group restated a “buy” rating and issued a $32.00 price objective on shares of Omeros in a research note on Friday, November 9th. Finally, Zacks Investment Research lowered shares of Omeros from a “hold” rating to a “sell” rating in a research note on Wednesday, February 6th. Two analysts have rated the stock with a sell rating, three have given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $27.56.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.com-unik.info/2019/02/13/teachers-advisors-llc-increases-position-in-omeros-co-omer.html.

Omeros Profile

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Further Reading: How much money do you need to begin day trading?

Want to see what other hedge funds are holding OMER? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omeros Co. (NASDAQ:OMER).

Institutional Ownership by Quarter for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit